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Rho family guanine nucleotide exchange factors (GEFs) regulate diverse cellular processes including cy-
toskeletal reorganization, cell adhesion, and differentiation via activation of the Rho GTPases. However, no
studies have yet implicated Rho-GEFs as molecular regulators of the mesenchymal cell fate decisions which
occur during development and repair of tissue damage. In this study, we demonstrate that the steady-state
protein level of the Rho-specific GEF GEFT is modulated during skeletal muscle regeneration and that gene
transfer of GEFT into cardiotoxin-injured mouse tibialis anterior muscle exerts a powerful promotion of
skeletal muscle regeneration in vivo. In order to molecularly characterize this regenerative effect, we extrap-
olate the mechanism of action by examining the consequence of GEFT expression in multipotent cell lines
capable of differentiating into a number of cell types, including muscle and adipocyte lineages. Our data
demonstrate that endogenous GEFT is transcriptionally upregulated during myogenic differentiation and
downregulated during adipogenic differentiation. Exogenous expression of GEFT promotes myogenesis of
C2C12 cells via activation of RhoA, Rac1, and Cdc42 and their downstream effector proteins, while a dominant-
negative mutant of GEFT inhibits this process. Moreover, we show that GEFT inhibits insulin-induced
adipogenesis in 3T3L1 preadipocytes. In summary, we provide the first evidence that the Rho family signaling
pathways act as potential regulators of skeletal muscle regeneration and provide the first reported molecular
mechanism illustrating how a mammalian Rho family GEF controls this process by modulating mesenchymal
cell fate decisions.
The Rho family of small GTPases has been shown to regu-
late a variety of cytoskeletal-dependent cell functions such as
cell morphology changes, formation of focal adhesions and
stress fibers, platelet aggregation, cytokinesis, cell cycle pro-
gression, and neurite outgrowth and guidance (27). In addi-
tion, the Rho family proteins are also involved in the differ-
entiation of many cell types, including neurons, T lymphocytes,
myocytes, adipocytes, and keratinocytes (11, 16, 19, 33). One
intriguing aspect of the Rho family is their role in regeneration
following injury. Rho family proteins have been shown to pro-
mote mouse and chick embryonic epidermal healing following
injury via formation of a rapidly assembled actin purse string
(7, 9, 69). Indeed, even in the adult, the Rho proteins play a
role in the formation of “re-epithelium” whereby the initial
inflammatory response leads to the influx of macrophages and
neutrophils, which subsequently release cytokines, growth fac-
tors, and nitric oxide to induce nearby keratinocytes to migrate
in a Rho protein-dependent manner across the wounded epi-
thelium (35, 81). In addition, the small GTPases are important
intracellular targets for promoting axon regrowth following
injury, whereby studies have shown that inactivation of RhoA
induces spontaneous plasticity of axonal and dendritic remod-
eling after spinal cord injury (25, 26, 30, 47). While several
reports have demonstrated the function of these proteins in
wound healing and neuronal regeneration, to date no studies
have examined the effects of the Rho family or its regulators in
skeletal muscle regeneration. This is surprising considering the
intimate function of this very important family of proteins in
skeletal muscle differentiation (11).
Damage to skeletal muscle occurs throughout life via sports
and other related activities, leading to a continuous recurrence
of regeneration in order to maintain proper muscle form. In
degenerating diseases such as diabetes and Duchenne muscu-
lar dystrophy, muscle regeneration is impaired and often leads
to the well-documented symptoms of these diseases. The pro-
cess of muscle regeneration, whether induced by everyday or
debilitating disease-induced damage, remains an active process
for long periods of time after the initial muscle injury. The
capacity of tissue for repair occurs via satellite stem cells lo-
cated between the basal lamina and the sarcolemma in mature
skeletal myofibers (39). Upon muscle injury, satellite cells exit
G0 and enter the cell cycle to proliferate. At this time, they
either renew the quiescent stem cell pool by reentering G0 or
differentiate into terminal myofibers.
The Rho family guanine nucleotide exchange factor GEFT
is capable of activating RhoA, Rac1, and Cdc42 via the catal-
ysis of the exchange of bound GDP for GTP on the Rho
proteins, thereby inducing their activation and the activity of
their downstream targets (10). Because GEFT has been shown
to be highly expressed in the adult skeletal muscle (10, 34), we
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sought to determine if this protein plays a role in the regulation
of skeletal muscle regeneration. Our data demonstrate that
endogenous GEFT protein levels are highly modulated during
the process of cardiotoxin-induced muscle injury and subsequent
regeneration of the mouse tibialis anterior muscle. Moreover,
infection of the tibialis anterior muscle with a GEFT-expressing
adeno-associated virus following cardiotoxin-induced skeletal
muscle injury resulted in significantly improved regeneration by
day 15 compared to vector control infection. Because muscle
regeneration involves the Rho family-dependent process of myo-
genesis, we examined the molecular mechanism by which GEFT
promotes skeletal muscle regeneration utilizing the multipotent
C2C12 mesenchymal progenitor cells which are capable of differ-
entiating into a number of cell types, including skeletal muscle
cells. Our studies demonstrate that GEFT is strongly expressed in
differentiated C2C12 myocytes, and, via activation of the Rho-
GTPases and their downstream signaling pathways, GEFT en-
hances the myogenic cascade, as evidenced by myotube formation
and an increased expression of differentiated muscle markers
following GEFT expression. In addition, our data demonstrate
that GEFT expression is downregulated during adipogenesis and
that exogenous expression of this protein strongly inhibits adipo-
genesis of 3T3L1 cells. Importantly, our novel findings are the
first reported which implicate the Rho-signaling pathways in the
regulation of skeletal muscle regeneration and which demon-
strate the involvement of a mammalian Rho family GEF in the
regulation of myogenic and adipogenic cell fate determination.
MATERIALS AND METHODS
Animal model of hind-limb muscle injury. Injury in the tibialis anterior muscle
was induced by injecting 25 l of 1 mM cardiotoxin (Sigma) as previously
described (4). To quantify cardiotoxin-induced injury and subsequent regenera-
tion, microphotographs of histological samples of transversal sections of the
tibialis anterior muscle were examined in a blinded fashion by two different
examiners. Quantification was performed on histological sections from the up-
per, middle, and lower regions of the tibialis anterior muscle (three sections per
region; n  6 animals per group). The areas of injury, as defined by absence or
subconfluence of myofiber formation, as well as the cross-sectional fiber area,
were quantified and expressed as the percentage  standard deviation.
Adeno-associated virus (AAV) production and infection. Human GEFT
cDNA was subcloned from a previously constructed GEFT-pCMVTag2B expres-
sion vector (10) into the EcoRI and XhoI sites of the pAAV-internal ribosome
entry site (IRES)-human recombinant green fluorescence protein (GFP) AAV2
vector (Stratagene). To produce the AAV2/8 viruses expressing human GEFT,
the AAV8 (p5E18-VD2/8) vector, the adeno-helper plasmid pAdF6, and
pAAV2-GEFT-IRES-hrGFP were cotransfected into 293 cells using the calcium
phosphate-mediated transfection method (31a). After 72 h of incubation, the
cells were harvested, pelleted down, and resuspended in lysis buffer (150 mM
NaCl, 50 mM Tris-HCl, pH 8.5). Purification of the virus was performed using an
Iodixanol density gradient centrifugation procedure as described previously (94,
95). The purified viral stocks were titrated using SYBR-Green real-time PCR to
determine the genome copies. As a control, vector AAVs were prepared as
described above.
In the hind-limb regeneration mouse model, the 3  1011 recombinant
AAV2/8 virus particles were injected in the tibialis anterior as previously de-
scribed (4). All experiments were performed in groups including 6 mice from 4
to 6 weeks of age.
In situ hybridization and immunohistochemistry. Digoxigenin (DIG)-labeled
GEFT-specific antisense and sense probes were produced using the DIG Nucleic
Acid Detection kit (Roche) according to the manufacturer’s directions and used
in in situ staining to detect GEFT mRNA expression in paraffin sections of adult
skeletal muscle using a DIG Wash and Block Buffer Set (Roche) according to the
manufacturer’s instructions.
For whole-mount in situ hybridization, embryos were rehydrated and subse-
quent Proteinase K digestion was performed according to stages between 7 min
and 1.5 h. Prehybridization was done in hybridization buffer (50% formamide, 50
g/ml heparin, 0,1% Tween 20, 5 mg/ml torula RNA, 5 SSC [1 SSC is 0.15
M NaCl plus 0.015 M sodium citrate]) at 65°C for 2 h. Denatured DIG-labeled
antisense (specific for GEFT) and sense (control) probes were hybridized for
12 h at 65°C. All washing steps were performed at 65°C. The first three washes
were done with 50% formamide–2 sodium citrate-sodium chloride-Tween 20
(SSCT) (two washes for 15 min, one wash for 30 min). These were followed by
two washes with 2 SSCT (15 min each) and two washes with 0.2 SSCT (15
min each). Blocking of the embryos was performed for 2 h with 5% sheep
serum–PTW (phosphate-buffered saline [PBS], pH 7.5, 0.1% Tween 20). The
embryos were incubated for 2 h in preabsorbed anti-DIG-probes at a 1:2,000
dilution in PTW. After eight washes for 10 min with PTW, two incubations of 7
min each with staining buffer (100 mM Tris-Cl, pH 9.5, 100 mM NaCl, 50 mM
MgCl2, 0.1% Tween 20) concluded the hybridization procedure. Staining was
done for a maximum of 6 h, whereby individual reactions were stopped according
to the signal intensity. The staining reaction was stopped by several washes with
PTW and postfixed overnight in 1% paraformaldehyde–PTW at 4°C.
Immunohistochemistry (IHC) of paraffin-embedded tissues was performed
using the ABC-Staining System according to manufacturer’s instructions (Santa
Cruz Biotechnology). All sections were counterstained with Harris Modified
Hematoxylin with acetic acid (Fisher Scientific). Anti-GEFT peptide antibody
raised in rabbits against the last 13 amino acids of the C terminus of GEFT
(Proteintech Group, Inc.) was used at a 1:100 dilution for IHC. Control IHC
experiments (data not shown) were performed using the rabbit preimmune
serum and anti-GEFT blocked with saturating levels of its specific peptide
antigen.
Northern blot analysis. Total RNA from cultured cells was isolated with Trizol
reagent (Invitrogen) according to the manufacturer’s instructions. RNA gel
electrophoresis and transfer onto nitrocellulose were performed by standard
techniques. Expression of GEFT or hypoxanthine-guanine phosphoribosyltrans-
ferase (HPRT) in C2C12 cell lysates was assayed via hybridization of a
[32P]dCTP-labeled gene-specific probe against the membrane. Radiolabeled
probes were purified using prepacked Sephadex G50 columns (Amersham).
Northern hybridizations were carried using standard methods, exposed to auto-
radiography film overnight, and then developed using a Kodak Processor.
Western blot analysis. To prepare whole-cell lysates, cells were lysed in cell
lysis buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 1 mM
phenylmethylsulfonyl fluoride [PMSF], 10 g/ml leupeptin, 10 g/ml aprotinin,
and 1 mM sodium orthovanadate). The insoluble material was excluded by
centrifugation. The resulting supernatant was mixed with sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) loading buffer and was sub-
jected to SDS-PAGE. After electrophoresis, the proteins were transferred to a
polyvinylidene difluoride membrane, and the blot was incubated with the appro-
priate primary antibody. Following incubation with the primary antibody, the
membrane was exposed to a horseradish peroxidase-conjugated secondary anti-
mouse, anti-rabbit, or anti-goat antibody, subjected to SuperSignal West Pico
Chemiluminescent reagent (Pierce Biotechnology, Inc.), and exposed to film.
Antibodies were used in the following dilutions: 1:1,000 anti-GEFT peptide
antibody (Proteintech Group, Inc.); 1:1,000 anti-actin (Santa Cruz Biotechnol-
ogy); 1:25 anti-F5D myogenin antibody (Developmental Studies Hybridoma
Bank; 1:25 anti-MF20 myosin heavy chain (MHC; Developmental Studies Hy-
bridoma Bank); 1:1,000 anti-RhoA (Santa Cruz Biotechnology); 1:1000 anti-
Rac1 (Santa Cruz Biotechnology); 1:300 anti-Cdc42 (Santa Cruz Biotechnology);
1:250 anti-phospho-Rho kinase (Thr396) (AnaSpec); 1:500 anti-Rho kinase
(paired nonphospho) (AnaSpec); 1:1,000 anti-Pak1 (Santa Cruz Biotechnology);
1:500 anti-phospho-Pak1 (Thr423) (Chemicon); 1:2,000 anti-phospho-p38 (Pro-
mega); 1:1,000 anti-p38 (Santa Cruz Biotechnology); 1:2,000 anti-phospho-JNK
(Promega); 1:1,000 anti-JNK (Santa Cruz Biotechnology); 1:2,500 anti-phospho-
p42/44 (Promega); 1:1,000 anti-p42/44 (Santa Cruz Biotechnology); 1:100 anti-
p21 (Santa Cruz Biotechnology); 1:25 anti-CT3 Troponin T (Developmental
Studies Hybridoma Bank); 1:250 anti-MyoD (Santa Cruz Biotechnology).
Reverse transcription-PCR (RT-PCR) analysis. Total RNA was isolated from
3T3L1 preadipocyte cells using Trizol reagent (Invitrogen). Total RNA of 1.0 g
was used as a template for first-strand cDNA synthesis using oligo(dT) as primer
in the presence of Superscript II reverse transcriptase (Invitrogen). One milliliter
of cDNA was subsequently used as a template for PCR amplification using Taq
polymerase (New England Biolabs).
Cell culture methodology. C2C12 cells were grown at subconfluent levels in
growth medium (GM) consisting of Dulbecco’s modified Eagle medium (DMEM)
(HyClone) supplemented with 10% fetal bovine serum (FBS) (HyClone). To induce
differentiation, cells were grown to 100% confluence and GM was replaced with
differentiation medium (DM) consisting of DMEM (HyClone) supplemented with
2% horse serum (Gibco). Stable transfected cells were selected in medium supple-
mented with 400 g/ml G418. DM was replaced every 24 h.
11090 BRYAN ET AL. MOL. CELL. BIOL.
 o
n
 Septem
ber 12, 2018 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
3T3L1 preadipocyte cells were grown at subconfluent levels in growth medium
(GM) consisting of DMEM (HyClone) supplemented with 10% bovine calf
serum (BCS) (Gibco). To induce differentiation, cells were grown to 100%
confluence and GM was replaced with differentiation medium (DM) consisting
of DMEM (HyClone) supplemented with 10% fetal calf serum (Gibco), 0.5 mM
isobutyl methyl xanthine (IBMX) (Sigma), 1 M dexamethasone (Sigma), and
500 ng/ml insulin (Sigma).
Plasmids and transfections. The pCMV-Tag2B mammalian expression vector
containing the human GEFT cDNA sequence was generated previously (11).
The dominant-negative GEFT mutant was generated using PCR with primers
specific for the gene resulting in the following amino acids of GEFT remaining:
165 to 467. RhoA, Rac1, and Cdc42 constructs were obtained from the Guthrie
cDNA Resource Center. Cells were transfected with Lipofectamine 2000 (In-
vitrogen) according to the manufacturer’s directions. For all experiments other
than reporter assays, pools of cells were stably selected with G418 prior to
experimental analysis. Via Western blot analysis, these pools were found to
exhibit a 5- to 10-fold increase in GEFT protein levels compared to vector-
transfected C2C12 and 3T3L1 cells (data not shown).
Immunofluorescence. Immunofluorescence for GFP was performed on frozen
sections of mouse muscle that were fixed in ice-cold methanol for 10 min and
washed in PBS. Cells growing on glass coverslips were fixed in ice-cold methanol
for 10 min, followed by 10 min of permeabilization in 0.1% Triton X-100 in PBS.
Reactions were blocked for 30 min with 0.2% bovine serum albumin, followed by
60 min of incubation with a rabbit polyclonal anti-GEFT antibody (1:100 dilu-
tion; Proteintech Group, Inc.), a mouse monoclonal MF-20 antibody (1:5 dilu-
tion; Iowa Hybridoma Bank), mouse monoclonal anti-FLAG epitope antibody
(1:500; Strategene), or rabbit polyclonal anti-hemagglutinin (HA) epitope anti-
body (1:500; Santa Cruz Biotechnology). Fluorescein-conjugated goat anti-rabbit
or goat anti-mouse antibody or Texas Red-conjugated anti-rabbit were added for
30 min (1:1,000; Molecular Probes). Polymerized actin was visualized by incu-
bation with Texas Red-conjugated phalloidin (1:1,000 dilution; Sigma). Nuclear
staining was observed after 10 min of 4,6-diamidino-2-phenylindole (DAPI)
treatment (1:500 dilution; Molecular Probes). Fluorescence images were cap-
tured at 400 on a CCD camera mounted on an inverted research microscope
using Ultraview imaging software (Olympus, Inc.).
GTPase activation assays. Lysates were incubated with glutathione S-trans-
ferase (GST)-rhotekin or GST-Pak1 previously bound to glutathione-Sepharose
beads and washed four times with lysis buffer, and associated GTP-bound forms
of RhoA, Rac1, or Cdc42 were released with protein loading buffer and revealed
by Western blot analysis.
Subcellular fractionation. Collected cells were washed with PBS and resus-
pended in 400 ml ice-cold cytoplasmic lysis buffer (10 mM HEPES, pH 7.9, 10
mM KCl, 0.1 mM EDTA, pH 8.0, 0.1 mM EGTA, 1 mM dithiothreitol, 1.0 mM
PMSF, 2 g/ml leupeptin, 2 g/ml aprotinin, 0.5 mg/ml benzamidine) and incu-
bated for 15 min on ice. A volume of 12.5 l of 10% NP-40 was added, the
reaction was centrifuged at full speed for 1 min, and the supernatant was col-
lected corresponding to the cytoplasmic extract. The pelleted nuclear extract was
resuspended in 25 l nuclear extraction buffer (20 mM HEPES, pH 7.9, 400 mM
NaCl, 1.0 mM EDTA, pH 8.0, 1.0 mM EGTA, pH 7.0) and incubated on ice for
30 min with intermittent vortexing. The nuclear extract was collected following
centrifugation.
Luciferase reporter assays. Cells were grown in 24-well plates and 1 g total
DNA per well was transfected using Lipofectamine (Invitrogen) according to the
manufacturers suggestions. Cells were harvested 24 h posttransfection for C2C12
cells or 48 h posttransfection for 3T3L1 cells in reporter lysis buffer (Promega).
Luciferase expression was detected with a luciferase assay system (Promega). As
a transfection control, -galactosidase (-gal) activities were determined with the
-gal reporter gene assay (Roche).
ORO staining. Oil Red O (ORO) staining for lipids was performed on 3T3L1
cells that were fixed with 4% paraformaldehyde, 0.2% Triton X-100 in PBS for
10 min and washed in PBS. The cells were then incubated with 0.6% (wt/vol) Oil
Red O solution (Avocado Research Chemicals Ltd.) dissolved in 50% dimethyl
sulfoxide for 1 h at room temperature.
RESULTS
Gene transfer of GEFT promotes skeletal muscle regenera-
tion following severe injury. Day-to-day wear and tear of adult
skeletal muscle accounts for approximately 1 to 2% replace-
ment of muscle fibers per week (75); however, mammalian
skeletal muscle has the ability to induce an extensive regener-
ation in response to severe damage. The use of myotoxins such
as bupivacaine, cardiotoxin, and notexin is perhaps the easiest
and most reproducible way to induce muscle regeneration
in animal models (23, 36–39). Muscle regeneration, both phys-
ically and chemically induced, is characterized by two phases: a
degenerative phase and a regenerative phase. For example, the
initial event of muscle degeneration following cardiotoxin in-
jection into the mouse tibialis anterior muscle is characterized
by significant necrosis of muscle fibers (Fig. 1A) and is accom-
panied by increased levels of muscle proteins, including myosin
heavy chain and myogenin (92) (Fig. 1B). Muscle degeneration
is followed by the onset of active muscle repair in which sat-
ellite stem cells from the basal lamina proliferate and differ-
entiate to fully repair the damaged skeletal muscle (17, 20, 42,
84).
Because the Rho family of small GTPases has been impli-
cated in the regulation of the myogenic cascade (11), we ex-
amined if this signaling pathway plays a role in skeletal muscle
regeneration following cardiotoxin-induced muscle regenera-
tion. The Rho family specific guanine nucleotide exchange
factor, GEFT, has been shown to be highly expressed in adult
skeletal muscle and can activate the small GTPases RhoA,
Rac1, and Cdc42 using both in vivo and in vitro assays (10, 34).
Western blot analysis of endogenous GEFT steady-state pro-
tein levels in untreated and cardiotoxin-injected tibialis ante-
rior muscles revealed high levels of GEFT in healthy muscle
tissue, accompanied by a significant reduction in expression
during the initial phases of muscle degeneration at 1, 3, and 5
FIG. 1. Infection of AAV2/8-GEFT in the mouse tibialis anterior
muscle. (A) Representative immunohistochemical sections of cardio-
toxin-injured tibialis anterior muscle sections stained with H&E and taken
from untreated and 1, 3, 5, 10, and 15 days postcardiotoxin-treated mus-
cles. (B) Western blot analysis was performed to examine the steady-state
protein levels of GEFT and the myogenic proteins, myosin heavy chain
and myogenin, during cardiotoxin-induced regeneration. (C) Western
blot analysis demonstrating sustained exogenous expression of GEFT in
normal tibialis anterior muscles at 48 h and 15 days postinfection. (D) Im-
munofluorescence of GFP signal from infected and uninfected mouse
tibialis anterior muscles taken 48 h and 15 days postinjection, further
demonstrating the sustained expression of the AAV2/8-GEFT virus.
VOL. 25, 2005 REGULATION OF MYOGENESIS AND ADIPOGENESIS BY GEFT 11091
 o
n
 Septem
ber 12, 2018 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
days postcardiotoxin injection (Fig. 1B). At 10 and 15 days
following cardiotoxin treatment, endogenous GEFT levels re-
turned to approximately the level of untreated muscles. These
data indicate that regulation of GEFT is important for skeletal
muscle regeneration and suggests that GEFT may play an
active role in this process. Additionally, these findings are
significant in that most GEFs are regulated posttranslationally,
while our data suggest that GEFT is regulated at the level of
expression.
The potential of adeno-associated virus (AAV)-mediated
gene transfer into cells has been exploited in multiple studies,
offering a unique opportunity to study the effects of gene ex-
pression for prolonged periods of time in vivo in the absence of
inflammatory or immune response (8, 21). To investigate di-
rectly whether GEFT might affect the regenerative capacity of
skeletal muscles during cardiotoxin-induced regeneration, we
injected purified 3  1011 AAV2/8-GEFT virus particles into
the cardiotoxin-damaged right tibialis anterior muscles of 4- to
6-week-old adult mice. Western blot analysis indicated that
exogenous GEFT is detectable within 48 h of infection and
remained high at least until 15 days postinfection (Fig. 1C).
Moreover, IRES-GFP signal was detected in frozen sections
collected from the infected muscle at 48 h after AAV2/
8-GEFT injection and remained strong at 15 days postinfec-
tion, while untreated muscle exhibited no significant back-
ground fluorescence, further confirming the fidelity and stabil-
ity of the AAV-GEFT virus for use in gene transfer in skeletal
muscle (Fig. 1D).
To explore the therapeutic potential of AAV2/8-GEFT ad-
ministration after skeletal muscle damage, we administered an
injection of 3  1011 AAV2/8-GEFT or control virus particles
directly into cardiotoxin-damaged mouse tibialis anterior mus-
cles and harvested the mice 15 days following initial muscle
damage. Compared to the control treatment, AAV2/8-GEFT
resulted in a remarkable improvement in the regeneration
process. While at day 15 after injury hematoxylin- and eosin-
stained (H&E) sections showed centronucleated myofibers in
both vector- and GEFT-treated muscles (a characteristic hall-
mark of regenerating muscle fibers), the damaged area in
AAV2/8-GEFT-treated muscles encompassed less than 10%
of the transversal muscle section area, compared with greater
than 40% of the control (Fig. 2A). To quantify the effect of the
AAV2/8-GEFT treatment more precisely, we measured the
myofiber density and muscle fiber cross-sectional area. Com-
pared to control treatment, GEFT-injected muscles exhibited
significantly more densely packed myofibers at 15 days post-
cardiotoxin injection (Fig. 2B). Moreover, the fiber area dis-
tribution of the control-injected muscles skewed to the right
and exhibited a much broader distribution of myofiber area,
indicative of less uniformly regenerated skeletal muscle fibers
(Fig. 2C). However, the distribution of the cross-sectional fiber
area was relatively narrow and symmetric in the AAV2/
8-GEFT-injected muscles, suggesting a more uniform myofiber
size indicative of regenerated muscle (Fig. 2D).
GEFT steady-state mRNA and protein levels are upregu-
lated during myogenic differentiation. Many of the signaling
pathways underlying skeletal muscle regeneration have been
identified and are highly studied. Intriguingly, many of these
pathways resemble those that are activated or repressed during
skeletal muscle formation from mesenchymal progenitor cells
during development. Indeed, whole-mount in situ hybridiza-
tion on mouse embryos at the embryonic days 9.5 to 13.5
exhibited a strong positive staining (dark staining) for GEFT
mRNA throughout the limb bud, suggesting that GEFT is
highly expressed and potentially important in mesodermal cells
which will specify the developing limb (Fig. 3A). Moreover,
terminally differentiated skeletal muscle of the adult hind limb
revealed intense staining of GEFT in skeletal muscle (s) but
not in bone (b) or adipocyte tissue (a) (Fig. 3B and C), sug-
gesting that GEFT is important not only for early skeletal
muscle differentiation but also in the muscle in adulthood.
In order to fully understand the molecular signaling path-
ways mediated by GEFT during skeletal muscle regeneration
and differentiation, we utilized the highly studied multipotent
C2C12 mesenchymal progenitor cells. Epithelial derived mes-
enchymal cells, muscle satellite cells, and cell lines such as
C2C12 cells are unique in that they are capable of differenti-
ating into a number of cell types, including chondrocytes, os-
teoblasts, myocytes, and adipocytes (1, 6, 59, 63, 65). Recently,
much interest has cumulated over the cell fate decision be-
tween myogenesis and adipogenesis, two lineages in which
regenerating satellite cells are capable of becoming myocytes
and adipocytes, suggesting that RhoA plays an important role
in the insulin-directed control of these two processes (73, 79).
In order to examine if GEFT may perform a function in this
process, we first examined the expression profiles of GEFT
during the C2C12 myogenic cascade and the 3T3L1 adipogenic
cascade. Specifically, upon serum starvation under high con-
fluence conditions, C2C12 cells will enter the myogenic cas-
cade, thus forming multinucleated myotubes and expressing
FIG. 2. Sustained expression of GEFT in cardiotoxin-damaged tib-
ialis anterior muscles induces muscle fiber regeneration. (A) H&E-
stained sections of tibialis anterior muscle from control and GEFT
AAV2/8-infected mice at 15 days after cardiotoxin-induced injury.
(B) Number of myofibers per 100-m2 area at 15 days postcardiotoxin
injection. (C and D) The fiber cross-sectional area distribution of
control and GEFT AAV2/8-infected tibialis anterior muscles mea-
sured at 15 days postcardiotoxin injection.
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markers of terminal skeletal muscle differentiation. As evi-
denced by both Northern and Western blot analyses, GEFT
mRNA and protein levels are highly upregulated upon sub-
jecting the cells to differentiation conditions (Fig. 3D and E).
As a control to demonstrate that the myogenic cascade is
occurring in our experiments, we examined the expression of
myogenin and MHC, both important muscle-specific proteins
that are strongly upregulated upon terminal myogenic differ-
entiation. Indeed, no myogenin or MHC is present in prolif-
erative conditions (GM); however, upon differentiation under
differentiation medium (DM), a strong band is detected for
myogenin and MHC, respectively, demonstrating the fidelity of
our experiments (Fig. 3F).
3T3L1 preadipocyte cells are capable, upon treatment with
isobutyl methyl xanthine (IMBX), dexamethasone, and insulin,
to differentiate from fibroblast cells to adipocyte cells (45).
These differentiated cells possess biochemical and morpholog-
ical features of adipocytes whereby differentiation is accompa-
nied by massive increases in the specific activities of enzymes
and receptors involved in fatty acid and triglyceride synthesis.
As opposed to the trends observed during C2C12 myogenesis,
we demonstrate that GEFT is significantly downregulated at
the steady-state mRNA and protein levels during 3T3L1 dif-
ferentiation with RT-PCR and Western blot analysis (Fig. 3G
and H). In order to demonstrate that we are truly differenti-
ating the 3T3L1 cells, we utilized RT-PCR to detect the ex-
pression of adipogenic markers, adipsin and peroxisome pro-
liferator-activated receptor 	 (PPAR	), both of which were
detectable in lanes correlating to differentiated 3T3L1 cells but
not in lanes correlating to undifferentiated cells (Fig. 3I).
Subcellular localization of GEFT in proliferating and dif-
ferentiated C2C12 cells. Immunofluorescent staining of endo-
genous GEFT was performed in proliferative growth conditions
(GM) and differentiating conditions (DM). In GM conditions,
endogenous GEFT appears to be exclusively cytoplasmic and
partially colocalizes with actin in a perinuclear fashion
(Fig. 4A). Fluorescent GEFT staining in C2C12 cells differen-
tiated for 5 days demonstrates a significantly stronger staining
in multinucleated myotubes (arrows) than in nonfused sur-
rounding cells (Fig. 4B), suggesting that in addition to the
initial upregulation of GEFT mRNA and protein levels upon
shift to DM treatment, a further increase in GEFT protein
expression occurs specifically in cells that have undergone
myotube fusion. A higher magnification examination of the
GEFT-rich myotubes illustrates that, while GEFT protein is
present throughout the cell, it is highly concentrated in actin-
rich regions lining the myotube (Fig. 4C). This unique subcel-
lular patterning occurs in approximately 40% of myotubes.
Moreover, no studies have examined the distinct subcellular
localization of GEFT. Therefore, we performed cytoplasmic-
nuclear fractionation of C2C12 cells under GM and DM con-
ditions, respectively. Given that no putative nuclear localiza-
FIG. 3. Expression of GEFT at mRNA and protein levels is highly
regulated during myogenesis and adipogenesis. (A) Whole-mount in
situ hybridizations of GEFT mRNA expression at mouse embryonic
days 9.5 to 13.5. (B and C) Immunohistochemical detection of GEFT
protein in the adult hind limb. Positive immunostaining appears brown
(a, adipocytes; b, bone; s, skeletal muscle). Magnification for panel B,
40; for panel C, 100. (D) Northern blot analysis of GEFT steady-
state mRNA expression in C2C12 cells subjected to proliferative
growth medium (GM) at 70% and 100% confluence as well as at days
4 and 7 of differentiation conditions (DM). As a loading control,
hypoxanthine-guanine phosphoribosyltransferase (HPRT) mRNA ex-
pression was detected. (E) Western blot analysis of GEFT steady-state
protein levels in C2C12 cells grown in growth medium (GM) or days 1
to 7 of differentiation (DM). (F) Analysis of myogenic markers by
Western blot. To ensure that myogenic differentiation is properly oc-
curring, Western blotting was performed in growth medium (GM) and
day 5 differentiation (DM) for the myogenic markers myogenin and
MHC. (G) RT-PCR detecting GEFT steady-state mRNA expression
in 3T3L1 cells subjected to nondifferentiation (GM) and days 1 to 6 of
differentiation (DM) conditions. (H) Western blot analysis of GEFT
steady-state protein levels in 3T3L1 cells subjected to nondifferentia-
tion (GM) and days 1 to 7 of differentiation (DM) conditions. (I) RT-
PCR analysis of adipogenic differentiation in growth medium (GM)
and day 4 differentiation (DM) for the adipogenic markers adipsin and
PPAR	.
FIG. 4. GEFT subcellular localization in C2C12 cells. Endogenous
GEFT subcellular localization was detected by immunofluorescence with
an anti-GEFT specific antibody in proliferative (A) and day 5 differenti-
ation (B) conditions (400magnification). (C) High-magnification image
of GEFT subcellular localization in a multinucleated myotube. (D) Anal-
ysis of GEFT in cytoplasmic and nuclear fractions of C2C12 cells in
growth medium (GM) and 4 days differentiation medium (DM). Western
blot analysis was performed with an anti-GEFT specific antibody to con-
firm the subcellular localization of GEFT in cytoplasm. HDAC, histone
deacetylase.
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tion sequence exists in the amino acid sequence, GEFT is
expressed exclusively in the cytoplasmic compartment in either
condition with no protein present in the nuclear fraction (Fig.
4D). Our previous studies have shown that GEFT is capable of
activating RhoA, Rac1, and Cdc42 (10, 34), and considering
that GEF activation often targets the Rho family to specific
subcellular regions, our data suggest that the activation of
these proteins occurs in the cytoplasm.
Activation of RhoA, Rac1, Cdc42, and their downstream
signaling cascades by GEFT. Our previous report (10) dem-
onstrated that GEFT functions as a promiscuous GEF, regu-
lating the activation of RhoA, Rac1, and Cdc42 in Neuro2A
cells. In order to examine if this trend holds true in C2C12
cells, we performed GTPase activation assays examining the
levels of the active GTP-bound forms of each GTPase. Active
Rac1 and Cdc42 were pulled down with GST bead-bound
Pak1, which is only capable of binding these two GTPases in
their active GTP-bound form, while active RhoA was pulled
down with GST bead-bound Rhotekin, which is only capable of
binding RhoA in its active GTP-bound form. Western blots
were performed with anti-RhoA, Rac1, and Cdc42-specific an-
tibodies detecting the active forms from the GST fusion pro-
tein pull-down assays as well as the total GTPase levels from
the cell lysate. As illustrated in Fig. 5A, exogenous expression
of GEFT promotes the active forms of all three GTPases in
either GM or DM conditions. Moreover, Pak1 and Rho kinase
are well studied downstream effectors of Rac1/Cdc42 and
RhoA, respectively, (18, 43, 54, 70). Using phosphospecific
Pak1 and Rho kinase antibodies, which only detects the acti-
vated forms of these proteins, we observe that GEFT strongly
upregulates the activation of these two proteins (Fig. 5B and
C), suggesting that GEFT mediates Rac1, Cdc42, and RhoA
pathways in this cell type. Additionally, Rac1 and Cdc42 are
known to regulate p38, JNK, and p42/44 mitogen-activated
protein kinase pathways (58, 83). Using phosphospecific anti-
bodies that recognize only the activated forms of these proteins
in Western blot analysis of vector- and GEFT-transfected cells,
we determined that GEFT is capable of strongly upregulating
the activation of these proteins (Fig. 5D to F), further provid-
ing evidence that GEFT signals, in addition to RhoA, through
the Rac1 and Cdc42 cascades. All three GTPase members have
been shown to regulate the subcellular localization of the
smooth, cardiac, and skeletal muscle-specific transcription fac-
tor serum response factor (SRF) (41, 50, 60, 61, 86), which has
been shown to upregulate essential myogenic proteins, includ-
ing 
-actin and MyoD (18, 32, 48, 74). In order to test whether
exogenous expression of GEFT is capable of regulating the
nuclear shuttling of SRF, we coexpressed either an untagged
empty vector or a FLAG-tagged GEFT expression vector with
an HA-tagged SRF expression vector in C2C12 cells. Immu-
nofluorescent staining demonstrates that in control cells, SRF
is localized both in the cytoplasm and nucleus (Fig. 5G to J),
while in GEFT-transfected cells, SRF is exclusively nuclear
(Fig. 5K to N), confirming that overexpression of GEFT is also
capable of regulating the nuclear translocation of this impor-
tant transcription factor involved in skeletal myogenesis.
GEFT promotes C2C12 skeletal myogenesis. C2C12 cells
are capable of proliferative growth when subjected to serum-
rich, subconfluent growth conditions (GM). However, upon
100% confluence and serum deprivation, these cells will with-
draw from the cell cycle, polarize with respect to each other,
and fuse to form multinucleated myotubes. In order to test the
overall effect of GEFT on myogenesis, we analyzed the GEFT-
mediated effects on the above-mentioned processes. GEFT
overexpression in C2C12 cells subjected to 3 days of differen-
tiation resulted in significantly more myotube formation than
vector cells (Fig. 6A to C). In addition, we observed that the
percentage of immunofluorescently labeled myosin heavy
chain-positive C2C12 cells was significantly higher in GEFT-
transfected cells than in vector-transfected cells (Fig. 6D to F).
Several molecular markers of myogenesis are commonly
used to judge the degree of differentiation in C2C12 cells.
Myosin heavy chain (MHC) (a structural component of muscle
fibers), MyoD (a transcription factor upregulated in myogen-
esis), myogenin (a transcription factor upregulated in myogen-
esis), troponin T (a structural component of the contractile
fibers), and p21 (a cell cycle inhibitor) have been shown to be
highly upregulated during differentiation (2, 3, 64, 93). West-
ern blot analysis of these markers demonstrates that p21, tro-
ponin T, myogenin, MyoD, and MHC are all upregulated at
FIG. 5. Regulation of RhoA, Rac1, Cdc42, and their downstream
signaling pathways in C2C12 cells by exogenous expression of GEFT.
(A) C2C12 cells were stably transfected with either a vector or GEFT
plasmids. Cell lysates were collected and RhoA, Rac1, and Cdc42 were
affinity purified by binding to GST-Rhotekin (for RhoA) or GST-Pak1
(for Rac1/Cdc42) beads. The protein bound to GST beads (active
forms) as well as the total protein were analyzed by Western blotting
with antibodies against RhoA, Rac1, or Cdc42. (B to F) Activation of
downstream protein kinases by GEFT. Vector or GEFT stably trans-
fected C2C12 cells were collected and the lysates were subjected to
Western blot analysis with phosphospecific antibodies specific for the
active, phosphorylated forms of (B) Rho kinase, (C) Pak1, (D) p38,
(E) JNK, and (F) p42/44. As a loading control, Western blotting was
performed with complementary antibodies (not phosphospecific) to
determine the total levels of each protein. (G) Nuclear translocation of
SRF promoted by GEFT. C2C12 cells were plated on glass coverslips
and transiently cotransfected HA-tagged SRF with either an empty
vector or FLAG-tagged GEFT. Immunofluorescent staining with anti-
FLAG and anti-HA antibodies reveal the subcellular localization of
SRF response to the presence or absence of exogenous GEFT.
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earlier time points in GEFT-transfected than vector-trans-
fected cells (Fig. 6G), suggesting that GEFT enhances the
progression of C2C12 cell myogenesis. Expression of these
protein markers, with the exception of MyoD (at equal levels
between vector and GEFT), is not detected at significant levels
in either vector- or GEFT-transfected cells under proliferating
conditions (data not shown).
GEFT promotes the regulation of myogenic markers via the
activation of RhoA, Rac1, and Cdc42. Many reports have at-
tempted to characterize the role of the Rho family GTPases
during skeletal myogenesis. While it appears to be universally
agreed that RhoA is essential in promoting this process, there
are conflicting reports as to the function of Rac1 and Cdc42 in
this process which are likely attributed to the reported limita-
tions of using dominant-negative and constitutively active mu-
tants of the Rho proteins (11). Because GEFT appears to
promiscuously regulate each of these GTPases in C2C12 cells,
we sought to determine which GEFT-mediated GTPase sig-
naling cascade is important for our observed promotion of
myogenesis. Using luciferase constructs driven by 4,800 bases
of the muscle creatine kinase (MCK) promoter (termed
MCK4800), SRF promoter, and 4RTK promoter (an artifical
promoter composed of four tandem E-box transcription factor
binding sites from the MCK promoter), we analyzed the ability
of GEFT together with RhoA, Rac1, or Cdc42 to regulate
these promoters. Overexpression of GEFT or any of the
GTPases resulted in a modest upregulation of SRF-driven
luciferase activity, while coexpression of GEFT with any single
GTPase exhibited strong synergistic activation of this reporter
construct (Fig. 7A), suggesting that GEFT is capable of regu-
lating SRF-target gene expression via any one of the GTPases.
In MCK4800 or 4RTK promoter-driven luciferase assays, ex-
pression of GEFT or any single GTPase again resulted in a
small increase in luciferase activity (Fig. 7B and C). However,
coexpression of GEFT with wild-type RhoA, Rac1, or Cdc42
exhibited a strong synergistic activation of MCK4800 and
4RTK luciferase expression. Lutz et al. (52) reported that a
C-terminal truncation of p63RhoGEF, a known splice variant
arising from the same gene as GEFT, resulted in a modest
dominant-negative effect on its downstream signaling path-
ways. Using a double N- and C-terminal truncation of GEFT
which leaves amino acids 165 to 467 (termed GEFT), we
demonstrate a dominant-negative effect that, in our hands, is
significantly greater than the single C-terminal truncation pre-
viously reported. In SRF, MCK, and 4RTK luciferase assays,
expression of this dominant-negative GEFT construct exhib-
ited a nearly 50% reduction compared to the vector level
(Fig. 7A to C). Cotransfection of any single Rho-GTPase with
FIG. 6. GEFT strongly upregulates biomarkers of myogenic differ-
entiation. (A and B) C2C12 cells, stably transfected with either vector
(A) or GEFT (B) plasmids, were subjected to differentiation condi-
tions. Photos were taken at day 3 of differentiation, showing a signif-
icant increase of myotubes in GEFT-expressing cells. (C) Histogram
illustrating the mean number of myotubes per vision field in vector-
and GEFT-transfected cells from growth media up to 5 days of differ-
entiation. The data are the means  standard errors of the means of
at least three independent experiments. (D and E) Immunofluorescent
staining with the myosin heavy chain-specific MF-20 antibody on vec-
tor (D) and GEFT (E) transfected C2C12 cells at day 2 of differenti-
ation. Myosin heavy chain-positive cells appear green. (F) Graph il-
lustrating the mean number of myosin heavy chain positive cells per
vision field in vector- and GEFT-transfected cells from growth media
up to 5 days differentiation. The data are means  standard errors of
the means of at least three independent experiments. (G) C2C12 cells
stably transfected with either vector control or GEFT were differen-
tiated, and cell lysates were collected at days 1, 2, and 3 of differenti-
ation. Subsequent Western blot analysis was performed to detect the
levels of different myogenic markers.
FIG. 7. Regulation of myogenic transcription factors by the GEFT-
mediated activation of the Rho proteins. C2C12 cells were cotrans-
fected with plasmids containing the luciferase reporter gene driven by
the (A) muscle creatine kinase (MCK4800), (B) serum response factor
(SRF), and (C) 4RTK promoter. Data are the means  standard
errors of the means of at least three independent experiments. Luc.
Act., luciferase activity.
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the dominant-negative GEFT mutant led to a significant re-
duction in the luciferase activity to a level well below the
expression of any single Rho-GTPase alone. These data sug-
gest that GEFT is capable of regulating myogenic gene expres-
sion via activation of RhoA, Rac1, and Cdc42. Moreover, ab-
lation of wild-type GEFT activity with a dominant-negative
GEFT mutant led to a significant reduction in the transcrip-
tional activation of the reporter genes, suggesting that at some
level, GEFT is essential for myogenic gene expression. Addi-
tionally, these data confirm several reports suggesting that
RhoA as well as Rac1 and Cdc42 are important positive reg-
ulators of myogenesis.
GEFT promotes MCK4800-luciferase activity through a
synergistic regulation of MyoD, E12, and E47. Myogenic reg-
ulatory factors bind as heterodimers with E proteins to E-box
consensus sites in the promoters of genes regulated at the
transcriptional level during myogenesis (12, 13, 14, 64, 67).
MyoD, one such myogenic regulatory factor, is capable of
binding with E12 or E47 in order to regulate the expression of
myogenic proteins. Using MCK4800-luciferase assays, we dem-
onstrate that singular transfection of GEFT or MyoD is capa-
ble of a moderate upregulation of MCK4800-luciferase activ-
ity, while a strong synergistic activation is observed upon
cotransfection of GEFT with MyoD (Fig. 8). Additionally,
cotransfection of GEFT and MyoD with either E12 or E47
resulted in a manyfold increase of luciferase activation com-
pared to transfection with any of these constructs alone, sug-
gesting that GEFT is capable of synergistically enhancing the
activity of MyoD and its binding partners, E12 and E47, to
activate genes and proteins involved in myogenesis. Again, use
of the dominant-negative GEFT mutant resulted in a signifi-
cant reduction in the activation of the MCK4800 luciferase
assays when expressed alone or when coexpressed with MyoD,
E12, or E47. These data suggest that activation of the Rho-
signaling pathways by GEFT, whether direct or indirect, can
synergistically promote E-box protein binding and activation of
myogenic regulatory factors, such as MyoD, to enhance the
expression of myogenic markers.
Inhibition of adipogenesis of 3T3L1 cells by GEFT. Muscle
satellite cells are believed to represent a committed stem cell
population that is responsible for the postnatal growth and
regeneration of skeletal muscle. However, many findings dem-
onstrate that cultured myoblasts are capable of differentiation
into multiple cell lineages, including osteocytes or adipocytes
(1, 6, 59, 65, 63). These observations suggest some degree of
plasticity within the mesenchymal lineage. To further investi-
gate this phenomenon, we explored the adipogenic potential of
mesenchymal lineages with respect to GEFT. Our data dem-
onstrate a strong down-regulation of GEFT expression, both at
the steady-state mRNA and protein levels, during 3T3L1 adi-
pogenesis (Fig. 3G and H), suggesting this protein may be
essential for maintaining the undifferentiated state of these
cells. In order to determine if GEFT can modulate the process
of adipogenesis, we utilized fibroblast-derived 3T3L1 preadi-
pocytes, which can be induced to differentiate into mature
adipocytic cells upon treatment with supersaturating levels of
insulin, dexamethasone, and IBMX. Fully differentiated 3T3L1
cells produce lipid granules that can be stained with Oil Red O
(ORO), which strongly binds to neutral lipids and fatty acids.
As a visual measure of the effect of GEFT on adipogenesis, we
quantitated ORO staining in 3T3L1 cells and found that vector
control cells exhibited significantly more stained lipid droplets
than GEFT-transfected cells (Fig. 9A and B). Additionally,
using RT-PCR analysis measuring the adipogenic markers ad-
ipsin, PPAR	, and Glut4, we observed a strong inhibition of
marker gene expression in GEFT-transfected cells compared
to vector transfected cells (Fig. 9C), demonstrating that GEFT
is capable of inhibiting the adipogenic program.
In order to further confirm that GEFT is capable of regu-
lating signaling cascades that are central in adipogenesis, the
effect of GEFT on PPAR	 and CRE-BP1 luciferase assays was
measured. PPAR	 is a nuclear hormone receptor induced very
early in the differentiation of several cultured adipocyte cell
lines and has been suggested to be a dominant regulator of the
AP2 gene which encodes an intracellular lipid binding protein
and is expressed only in adipose cells (28, 29, 68). Cotransfec-
tion of GEFT with the PPAR	 luciferase construct resulted in
a reduction from baseline luciferase activity, while cotransfec-
tion with the dominant-negative GEFT truncation mutant re-
sulted in a modest increase of luciferase activity (Fig. 9D).
Moreover, cotransfection with a PPAR	 expression vector led
to a strong increase in PPAR	-mediated luciferase activity,
while expression of GEFT strongly down-regulated the PPAR	-
mediated luciferase activity. Coexpression of PPAR	 with the
dominant-negative GEFT truncation mutant resulted in a
modest increase in activation of the PPAR	 reporter.
The activating transcription factor CRE-BP1 (also called
ATF2) binds to both AP-1 and CRE DNA response elements
and is a member of the ATF/CREB family of leucine zipper
proteins (46). CRE-BP1 has been implicated in the transcrip-
tional regulation of cytokines, cell cycle control, and apoptosis.
This transcription factor is an important substrate of signals
upstream of the activation of genes associated with promoting
adipogenesis. As indicated in Fig. 9E, cotransfection of GEFT
with the CRE-BP1 responsive trans-reporter construct resulted
in a strong decrease in activity compared to the vector control,
again demonstrating that GEFT is capable of inhibiting adi-
pogenesis-responsive signaling pathways. Moreover, a modest
increase in luciferase activity compared to the vector control was
observed with transfection of the dominant-negative GEFT trun-
FIG. 8. GEFT promotes the activation of MyoD and its hetero-
meric binding partners, E12 and E47. C2C12 cells were cotransfected
with plasmids containing the luciferase reporter gene driven by the
muscle creatine kinase (MCK4800) promoter. Data are the means 
standard errors of the means of at least three independent experi-
ments. Luc. Act., luciferase activity.
11096 BRYAN ET AL. MOL. CELL. BIOL.
 o
n
 Septem
ber 12, 2018 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
cation mutant. Together, these data suggest that GEFT down-
regulates the adipogenic cascade by inhibiting the transcriptional
activation of PPAR	 and CRE-BP1.
DISCUSSION
Data from our laboratory demonstrate that the Rho family
GEF GEFT regulates important signaling pathways involved
in the processes of skeletal muscle regeneration and myogenic
differentiation. Our findings represent the first reported study
to show that Rho-signaling pathways are capable of regulating
skeletal muscle regeneration and are also the first to implicate,
at the molecular level, a Rho-GEF in the process of myogenic-
adipogenic cell fate determination. Our data show that GEFT
steady-state protein levels are modulated during cardiotoxin-
induced skeletal muscle regeneration, and infection of mouse
skeletal muscle with AAV-GEFT led to a substantial enhance-
ment on muscle regeneration compared to the control. We
sought to characterize the molecular mechanisms controlling
this process by utilizing well-established differentiation models.
GEFT steady-state mRNA and protein levels were found to be
strongly increased during myogenic differentiation of multipo-
tent mesenchymal C2C12 cells and downregulated during adi-
pogenic differentiation of fibroblastic 3T3L1 preadipocytes. To
gain insight into the role of GEFT in mesenchymal cell fate
determination, we expressed this protein in C2C12 and 3T3L1
cells and examined its effect on myogenesis and adipogenesis,
respectively. We found that GEFT strongly promotes myogen-
esis in C2C12 cells through activation of RhoA, Rac1, and
Cdc42 and, conversely, inhibits the adipogenic program in
3T3L1 cells. Our data suggest that during skeletal muscle re-
generation, GEFT promotes the myogenic lineages of infiltrat-
ing progenitor cells, thus promoting the healing process after
injury.
Expression of GEFT in vivo and during in vitro cell differ-
entiation. At present, there are over 70 known Rho family
GEFs in mammals (71). This striking number of proteins, each
with similar functions and targets, is due in part to the remark-
able temporal and spatial complexity of the mammalian devel-
opment and function. Aside from tissue-specific expression,
most GEFs are regulated at the level of posttranslational mod-
ifications, including phosphorylation, subcellular localization,
and protein-protein interactions. GEFT appears to be unique
in that it is regulated highly at the transcriptional level. This is
not surprising, given that GEFT is one of the smallest known
GEFs with limited N and C termini and putative regulatory
domains. Consistent with our observations that GEFT expres-
sion is modulated during the skeletal muscle regeneration pro-
cess, we find that upon differentiation of C2C12 cells, GEFT
steady-state mRNA and protein levels are strongly upregu-
lated. Interestingly, skeletal muscle differentiation undergoes
dual regulation by both growth factor abundance and cell ad-
hesion. Endogenous C2C12 GEFT levels remained low in
growth medium where cells were either 70% confluent or
100% confluent; however, the upregulation occurred upon se-
rum deprivation, suggesting that GEFT expression is not reg-
ulated in a cell contact-dependent manner but perhaps in
response to growth factor concentrations. Furthermore, immu-
nofluorescence analysis of endogenous GEFT localization re-
veals that during differentiation, GEFT expression is higher in
multinucleated myotubes than in nonmyotube cells, suggesting
that GEFT is markedly upregulated in a certain percentage of
the cells in the later stages of myogenic differentiation. This
finding is consistent with our observation that GEFT steady-
state protein levels are upregulated late in the regenerative
process at 10 and 15 days postcardiotoxin injection. The up-
regulation of GEFT during myogenesis is not surprising given
that the GEFT promoter contains many high-stringency puta-
tive myogenic regulatory factor and SRE elements, both of
which play essential roles as regulatory elements in the genes
of important function during myogenic differentiation.
Muscle satellite cells possess multipotential mesenchymal
stem cell activity and are capable of forming osteocytes and
adipocytes as well as myocytes. Intracellular and extracellular
signals are responsible for the cell fate decision during muscle
regeneration toward the formation of myoblasts but not adi-
pocytes or other incorrect cell types. As an excellent model
system to examine adipogenesis, 3T3L1 preadipocyte cells are
capable of differentiation from fibroblast cells to adipocyte
cells upon treatment with IMBX, dexamethasone, and insulin.
In correlation to our IHC experiments, differentiation of 3T3L1
preadipocytes results in a substantial decrease in GEFT
steady-state mRNA and protein levels by day 3 of treatment.
Interestingly, day 3 to 4 of treatment marks a well studied
biochemical switch in 3T3L1 differentiation where adipogenic
FIG. 9. GEFT inhibits adipogenesis in 3T3L1 cells. (A) Oil Red O
staining of vector- and GEFT-transfected 3T3L1 cells subjected to 5 days
of differentiation. (B) Histogram illustrating the mean number of Oil Red
O lipid droplets per cell in vector- and GEFT-transfected 3T3L1 cells at
day 5 of differentiation. The data are means  standard errors of the
means of at least three independent experiments. P  0.05 by Student’s t
test. (C) 3T3L1 preadipocyte cells were stably transfected with vector
control or GEFT. Cell lysates were collected in growth media (GM) and
days 1, 3, and 5 of differentiation (DM). Subsequent RT-PCR analysis was
performed for the adipogenic markers adipsin, PPAR	, and Glut4. (D
and E) 3T3L1 cells were cotransfected with plasmids containing the lu-
ciferase reporter gene driven by the (D) PPAR	 and (E) the CRE-BP1
promoter. Data are the means  standard errors of the means of at least
three independent experiments.
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markers, including adipsin, PPAR	, and Glut4, have been
shown to be strongly upregulated, triglycerides are produced,
and intracellular lipid granules begin to accumulate. An inter-
esting observation is that though we observe a reduction in
GEFT activity by day 4 of differentiation, its levels are still
present, albeit at a lower level, up to day 7 of differentiation,
suggesting that much like members of the Rho-GTPases, there
are likely more complex functions than simply a “black and
white” role for this protein during adipogenesis.
GEFT regulates the Rho family of small GTPases and their
downstream signaling pathways. GEFT has been shown to
regulate RhoA, Rac1, and Cdc42 in a cell-type-specific manner
(10, 34). In order to examine the signaling pathways modulated
by GEFT during the mesenchymal cell fate decision, a process
that is essential for skeletal muscle repair, we exogenously
expressed GEFT in undifferentiated multipotent C2C12 cells
and assayed the activation of the Rho family and their down-
stream signaling pathways. Similar to our previous report (10),
GEFT is capable of promiscuously activating RhoA, Rac1, and
Cdc42 in C2C12 cells. In this study, we observed a GEFT-
mediated activation of Pak1, Rho-kinase, p38, JNK, and p42/
p44, all important downstream effectors of the Rho family. It is
interesting to note that, while p38 is essential for skeletal
myogenesis to occur (5, 15, 22, 49), this process is strongly
inhibited by JNK (56, 57, 72). Indeed, for myogenesis to occur
correctly, JNK must be down-regulated either at the level of
expression or activity; however, the mechanism by which this
occurs remains unknown. The overactivation of JNK by use of
constitutively active mutants of Rac1 and Cdc42 in previous
reports likely contributes to the controversial ideology that
Rac1 and Cdc42 ultimately lead to the inhibition of myo-
genesis.
C2C12 skeletal myogenesis is enhanced upon exogenous
expression of GEFT. Given the recent high-profile studies il-
lustrating that RhoA and its regulator, p190-B RhoGAP, are
essential mediators in the IGF-1-mediated mesenchymal cell
fate decision between myogenesis and adipogenesis (73, 78,
79), we were prompted to examine if GEFT, given its unique
expression patterns in vivo and during myogenesis and adipo-
genesis in cell culture, is capable of regulating this process in a
similar manner. To date, no mammalian GEFs have been
molecularly implicated in directly controlling either myogen-
esis or adipogenesis. One study has suggested that the well
studied Trio-GEF could play a role in myogenic differentiation
(62). While the proliferation of secondary myoblasts appeared
normal in Trio-deficient mice, terminally differentiated sec-
ondary myofibers were absent, possibly due to defects in myo-
blast alignment or fusion. However, no molecular character-
ization of the role of Trio in myogenesis has been reported.
Interestingly, Trio is highly homologous to and expressed in
the same adult tissues as GEFT, with the highest adult expres-
sion in the brain, heart, and skeletal muscle (24). This suggests
that these two proteins may perform similar functions in the
same systems; however, it poses the question as to why there is
redundancy of these two proteins in the adult brain, heart, and
skeletal muscle.
In this report, we present several lines of evidence suggest-
ing that GEFT promotes myogenesis via its downstream tar-
gets: RhoA, Rac1, and Cdc42. GEFT is capable of enhancing
myotube formation and key proteins involved in myogenesis,
including myosin heavy chain, myogenin, and muscle creatine
kinase, among many others. Observations that GEFT mediates
myogenesis via RhoA, Rac1, and Cdc42 are interesting given
that the roles of the Rho proteins in myogenesis are highly
controversial (11). It is generally agreed that RhoA promotes
myogenesis in a number of cell lines via its activation of SRF
and MyoD (18, 60, 66, 76, 80), while the roles of Rac1 and
Cdc42 remain a point of argument. Previous reports have dem-
onstrated negative roles for these two GTPases (31, 40, 57) as
well as positive roles (51, 82, 85). A recent study suggests that
each GTPase is regulated in a temporal manner in order for
proper myogenic differentiation to occur (85). This implies that
previous reports revealing an inhibitory role of Rac1 and
Cdc42 are likely artifacts of the limitation of using constitu-
tively active and dominant-negative mutants to examine a pro-
cess that is composed of multiple stages leading to terminal
differentiation. We circumvented the use of dominant-negative
and constitutively active mutants in our experiments by simply
activating exogenous wild-type RhoA, Rac1, and Cdc42 by
cotransfection with GEFT, thus demonstrating that all three
GTPases can promote skeletal myogenesis.
To date, no reports have attempted to knock down the effect
of endogenous GEFT with small interfering RNA. Unfortu-
nately, after multiple unsuccessful attempts by our laboratory
to generate effective GEFT-specific retroviral RNA interfer-
ence constructs or small interfering oligonucleotides, we opted
to utilize a dominant-negative mutant of GEFT based on a
previously reported mutant of p63RhoGEF, a splice variant of
GEFT arising from the same gene (52). Use of the double N-
and C-terminal truncation dominant-negative GEFT mutant in
several assays measuring the progression of myogenesis dem-
onstrate that when GEFT activity is inhibited, myogenesis is
strongly hampered, suggesting GEFT expression is essential
for proper myogenesis to occur.
3T3L1 adipogenesis is inhibited upon exogenous expression
of GEFT. Progenitor cells which infiltrate damaged skeletal
muscle have the capacity to differentiate into multiple cell
lineages. However, a variety of signaling pathways must be
precisely regulated in order to ensure that myogenic cell fate
determination in maintained. Sordella et al. (79) demonstrated
that differential activation of RhoA in response to IGF-1 pro-
vides an important switching mechanism in the cell fate deci-
sion between myogenesis and adipogenesis, and that the phos-
phorylation status of the Rho regulator, p190-B RhoGAP,
controls this switch and consequently determines how the cell
will respond to the IGF-1 stimulus. This report illustrates that
the regulation of RhoA GTPase activity appears to be an
important determinant of cell fate in the differentiation of
adipocyte and myocyte precursors. Our data demonstrate that
GEFT steady-state mRNA and protein levels are significantly
downregulated upon adipogenic differentiation, suggesting
that GEFT could function as an inhibitor of adipocyte differ-
entiation. Using 3T3L1 preadipocyte cells, which undergo adi-
pocyte differentiation in response to supersaturating levels of
IBMX, dexamethasone, and insulin, we demonstrated that
GEFT is capable of inhibiting adipogenesis, as evidenced by
decreased lipid granule staining and inhibition of PPAR	,
CRE-BP1, adipsin, and Glut4 expression, all markers of adi-
pocyte differentiation. Moreover, a modest increase in the adi-
pogenic cascade was observed in all adipogenesis assays per-
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formed with the dominant-negative GEFT mutant, suggesting
that when the Rho-signaling pathways are inhibited, adipogen-
esis is enhanced.
Similar to the conflicting reports on the role of the Rho-
GTPase in skeletal muscle differentiation, much confusion ex-
ists as to the precise mechanism by which these proteins reg-
ulate the adipogenic program. The Rho family has been shown
to regulate adipogenesis, though the exact function of the
GTPases in this process is largely unknown. In addition the
RhoA and p190-B RhoGAP control of IGF-1-induced adipo-
genesis (78, 79), one recent study demonstrated that in human
mesenchymal stem cells (hMSCs), expression of dominant-
negative RhoA committed hMSCs to become adipocytes, while
constitutively active RhoA promoted osteogenesis (55). Al-
though several studies indicate that RhoA inhibits adipogenic
differentiation, other reports demonstrate findings to the con-
trary. For example, insulin-stimulated prenylation of RhoA
assures normal phosphorylation and activation of CREB that
triggers the intrinsic cascade of adipogenesis (44). Moreover,
these authors conclude that inhibition of RhoA prenylation
arrests insulin-stimulated adipogenesis. In insulin-sensitive
cells, such as adipocytes and skeletal muscle, the activation of
phosphoinositide 3-kinase (PI3K) is thought to be critical in
allowing insulin to stimulate both the uptake of glucose and the
translocation of a specialized glucose transporter, Glut4, to the
plasma membrane (77, 87–91). One study provides direct evi-
dence that PI3K does not use Rac1 to couple the insulin
receptor to glucose uptake in adipocytes (53), suggesting that
some of the specificity in the biological responses elicited by
PI3K may be mediated by the activation of different effector
molecules. However, Cdc42 has been shown to mediate insulin
signaling to Glut4 translocation and lies downstream of G
alpha (q/11) and upstream of PI3K and protein kinase C
lambda in this stimulatory pathway (86a).
In conclusion, our data indicate that Rho-signaling cascades
activated by GEFT play a role in modulating skeletal muscle
regeneration. Moreover, we have demonstrated GEFT, a GEF
for the Rho family of GTPases, to be the first mammalian GEF
reported to regulate mesenchymal cell fate decisions. Further-
more, we provide evidence suggesting that GEFT is capable of
modulating the myogenic verses adipogenic cell fate decision
of progenitor mesenchymal cells. These findings offer impor-
tant contributions to our present understanding of the role of
the Rho-GTPases and their regulator, GEFT, in skeletal mus-
cle regeneration and mesenchymal differentiation, demonstrat-
ing that GEFT is capable of promoting skeletal muscle regen-
eration via a RhoA-, Rac1-, and Cdc42-mediated enhancement
of myogenesis and inhibition of adipogenesis.
ACKNOWLEDGMENTS
We thank Xin-Hua Feng at Baylor College of Medicine for the use
of C2C12 cells and Xiang Tong in the Children’s hospital at Baylor
College of Medicine for the use of 3T3L1 cells. We also thank Robert
Schwartz at Texas A&M University HSC-IBT for the SRF-HA mam-
malian expression vector and Stephen Safe at Texas A&M University
HSC for the PPAR	 reporter construct and the PPAR	 mammalian
expression vector.
This work is partially supported by the NIH grant 5 R01 HL064792
to M.L.
REFERENCES
1. Akimoto, T., T. Ushida, S. Miyaki, H. Akaogi, K. Tsuchiya, Z. Yan, R. S.
Williams, and T. Tateishi. 2005. Mechanical stretch inhibits myoblast-to-
adipocyte differentiation through Wnt signaling. Biochem. Biophys. Res.
Commun. 329:381–385.
2. Arnold, H. H., and T. Braun. 2000. Genetics of muscle determination and
development. Curr. Top. Dev. Biol. 48:129–164.
3. Arnold, H. H., and B. Winter. 1998. Muscle differentiation: more complexity
to the network of myogenic regulators. Curr. Opin. Genet. Dev. 8:539–544.
4. Arsic, N., S. Zacchigna, L. Zentilin, G. Ramirez-Correa, L. Pattarini, A.
Salvi, G. Sinagra, and M. Giacca. 2004. Vascular endothelial growth factor
stimulates skeletal muscle regeneration in vivo. Mol. Ther. 10:844–854.
5. Baeza-Raja, B., and P. Munoz-Canoves. 2004. p38 MAPK-induced nuclear
factor-kappaB activity is required for skeletal muscle differentiation: role of
interleukin-6. Mol. Biol. Cell 15:2013–2026.
6. Bains, W., P. Ponte, H. Blau, and L. Kedes. 1984. Cardiac actin is the major
actin gene product in skeletal muscle cell differentiation in vitro. Mol. Cell.
Biol. 4:1449–1453.
7. Bement, W. M., C. A. Mandato, and M. N. Kirsch. 1999. Wound-induced
assembly and closure of an actomyosin purse string in Xenopus oocytes.
Curr. Biol. 9:579–587.
8. Bouchard, S., T. C. MacKenzie, A. P. Radu, S. Hayashi, W. H. Peranteau, N.
Chirmule, and A. W. Flake. 2003. Long-term transgene expression in cardiac
and skeletal muscle following fetal administration of adenoviral or adeno-
associated viral vectors in mice. J. Gene Med. 5:941–950.
9. Brock, J., K. Midwinter, J. Lewis, and P. Martin. 1996. Healing of incisional
wounds in the embryonic chick wing bud: characterization of the actin
purse-string and demonstration of a requirement for Rho activation. J. Cell
Biol. 135:1097–1107.
10. Bryan, B., V. Kumar, L. J. Stafford, Y. Cai, G. Wu, and M. Liu. 2004. GEFT,
a Rho family guanine nucleotide exchange factor, regulates neurite out-
growth and dendritic spine formation. J. Biol. Chem. 279:45824–45832.
11. Bryan, B. A., D. Li, X. Wu, and M. Liu. 2005. The Rho family of small
GTPases: crucial regulators of skeletal myogenesis. Cell Mol. Life Sci. 62:
1547–1555.
12. Buckingham, M. 2001. Skeletal muscle formation in vertebrates. Curr. Opin.
Genet. Dev. 11:440–448.
13. Buckingham, M. 2003. How the community effect orchestrates muscle dif-
ferentiation. Bioessays 25:13–16.
14. Buckingham, M., L. Bajard, T. Chang, P. Daubas, J. Hadchouel, S. Meilhac,
D. Montarras, D. Rocancourt, and F. Relaix. 2003. The formation of skeletal
muscle: from somite to limb. J. Anat. 202:59–68.
15. Cabane, C., W. Englaro, K. Yeow, M. Ragno, and B. Derijard. 2003. Regu-
lation of C2C12 myogenic terminal differentiation by MKK3/p38alpha path-
way. Am. J. Physiol. Cell Physiol. 284:C658–666.
16. Cantrell, D. A. 2003. GTPases and T cell activation. Immunol. Rev. 192:122–
130.
17. Cao, B., and J. Huard. 2004. Muscle-derived stem cells. Cell Cycle 3:104–
107.
18. Carnac, G., M. Primig, M. Kitzmann, P. Chafey, D. Tuil, N. Lamb, and A.
Fernandez. 1998. RhoA GTPase and serum response factor control selec-
tively the expression of MyoD without affecting Myf5 in mouse myoblasts.
Mol. Biol. Cell 9:1891–1902.
19. Charrasse, S., M. Causeret, F. Comunale, A. Bonet-Kerrache, and C. Gauthier-
Rouviere. 2003. Rho GTPases and cadherin-based cell adhesion in skeletal
muscle development. J. Muscle Res. Cell Motil. 24:309–313.
20. Chen, J. C., and D. J. Goldhamer. 2003. Skeletal muscle stem cells. Reprod.
Biol. Endocrinol. 1:101.
21. Chirmule, N., K. Propert, S. Magosin, Y. Qian, R. Qian, and J. Wilson. 1999.
Immune responses to adenovirus and adeno-associated virus in humans.
Gene Ther. 6:1574–1583.
22. Cuenda, A., and P. Cohen. 1999. Stress-activated protein kinase-2/p38 and a
rapamycin-sensitive pathway are required for C2C12 myogenesis. J. Biol.
Chem. 274:4341–4346.
23. d’Albis, A., R. Couteaux, C. Janmot, A. Roulet, and J. C. Mira. 1988. Re-
generation after cardiotoxin injury of innervated and denervated slow and
fast muscles of mammals. Myosin isoform analysis. Eur. J. Biochem. 174:
103–110.
24. Debant, A., C. Serra-Pages, K. Seipel, S. O’Brien, M. Tang, S. H. Park, and
M. Streuli. 1996. The multidomain protein Trio binds the LAR transmem-
brane tyrosine phosphatase, contains a protein kinase domain, and has
separate rac-specific and rho-specific guanine nucleotide exchange factor
domains. Proc. Natl. Acad. Sci. USA 93:5466–5471.
25. Dergham, P., B. Ellezam, C. Essagian, H. Avedissian, W. D. Lubell, and L.
McKerracher. 2002. Rho signaling pathway targeted to promote spinal cord
repair. J. Neurosci. 22:6570–6577.
26. Ellezam, B., C. Dubreuil, M. Winton, L. Loy, P. Dergham, I. Selles-Navarro,
and L. McKerrac. 2002. Inactivation of intracellular Rho to stimulate axon
growth and regeneration. Prog. Brain Res. 137:371–380.
27. Etienne-Manneville, S., and A. Hall. 2002. Rho GTPases in cell biology.
Nature 420:629–635.
VOL. 25, 2005 REGULATION OF MYOGENESIS AND ADIPOGENESIS BY GEFT 11099
 o
n
 Septem
ber 12, 2018 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
28. Fajas, L., M. B. Debril, and J. Auwerx. 2001. Peroxisome proliferator-acti-
vated receptor-gamma: from adipogenesis to carcinogenesis. J Mol. Endo-
crinol. 27:1–9.
29. Farmer, S. R. 2005. Regulation of PPARgamma activity during adipogenesis.
Int. J. Obes. Relat. Metab. Disord. 29(Suppl. 1):S13–S16.
30. Fournier, A. E., B. T. Takizawa, and S. M. Strittmatter. 2003. Rho kinase
inhibition enhances axonal regeneration in the injured CNS. J. Neurosci.
23:1416–1423.
31. Gallo, R., M. Serafini, L. Castellani, G. Falcone, and S. Alema. 1999. Distinct
effects of Rac1 on differentiation of primary avian myoblasts. Mol. Biol. Cell
10:3137–3150.
31a.Gao, G. P., M. R. Alvira, L. Wang, R. Calcedo, J. Johnston, and J. M. Wilson.
2002. Novel adeno-associated viruses from rhesus monkeys as vectors for
human gene therapy. Proc. Natl. Acad. Sci. USA 99:11854–11859.
32. Gauthier-Rouviere, C., M. Vandromme, D. Tuil, N. Lautredou, M. Morris,
M. Soulez, A. Kahn, A. Fernandez, and N. Lamb. 1996. Expression and
activity of serum response factor is required for expression of the muscle-
determining factor MyoD in both dividing and differentiating mouse C2C12
myoblasts. Mol. Biol. Cell 7:719–729.
33. Govek, E. E., S. E. Newey, and L. Van Aelst. 2005. The role of the Rho
GTPases in neuronal development. Genes Dev. 19:1–49.
34. Guo, X., L. J. Stafford, B. Bryan, C. Xia, W. Ma, X. Wu, D. Liu, Z. Songyang,
and M. Liu. 2003. A Rac/Cdc42-specific exchange factor, GEFT, induces cell
proliferation, transformation, and migration. J. Biol. Chem. 278:13207–13215.
35. Hackam, D. J., and H. R. Ford. 2002. Cellular, biochemical, and clinical
aspects of wound healing. Surg. Infect. 3(Suppl. 1):S23–S35.
36. Hall-Craggs, E. C. 1974. Rapid degeneration and regeneration of a whole
skeletal muscle following treatment with bupivacaine (Marcain). Exp. Neu-
rol. 43:349–358.
37. Harris, J. B. 2003. Myotoxic phospholipases A2 and the regeneration of
skeletal muscles. Toxicon 42:933–945.
38. Harris, J. B., and M. A. Johnson. 1978. Further observations on the patho-
logical responses of rat skeletal muscle to toxins isolated from the venom of
the Australian tiger snake, Notechis scutatus scutatus. Clin. Exp. Pharmacol.
Physiol. 5:587–600.
39. Harris, J. B., and C. A. Maltin. 1982. Myotoxic activity of the crude venom
and the principal neurotoxin, taipoxin, of the Australian taipan, Oxyuranus
scutellatus. Br. J. Pharmacol. 76:61–75.
40. Heller, H., E. Gredinger, and E. Bengal. 2001. Rac1 inhibits myogenic dif-
ferentiation by preventing the complete withdrawal of myoblasts from the
cell cycle. J. Biol. Chem. 276:37307–37316.
41. Hill, C. S., J. Wynne, and R. Treisman. 1995. The Rho family GTPases
RhoA, Rac1, and CDC42Hs regulate transcriptional activation by SRF. Cell
81:1159–1170.
42. Huard, J., B. Cao, and Z. Qu-Petersen. 2003. Muscle-derived stem cells:
potential for muscle regeneration. Birth Defects Res. C Embryo Today
69:230–237.
43. Jaffer, Z. M., and J. Chernoff. 2002. p21-activated kinases: three more join
the Pak. Int. J. Biochem. Cell. Biol. 34:713–717.
44. Klemm, D. J., J. W. Leitner, P. Watson, A. Nesterova, J. E. Reusch, M. L.
Goalstone, and B. Draznin. 2001. Insulin-induced adipocyte differentiation.
Activation of CREB rescues adipogenesis from the arrest caused by inhibi-
tion of prenylation. J. Biol. Chem. 276:28430–28435.
45. Langer-Safer, P. R., S. R. Lehrman, and A. M. Skalka. 1985. v-src inhibits
differentiation via an extracellular intermediate(s). Mol. Cell. Biol. 5:2847–
2850.
46. Lee, M. Y., H. J. Kong, and J. Cheong. 2001. Regulation of activating
transcription factor-2 in early stage of the adipocyte differentiation program.
Biochem. Biophys. Res. Commun. 281:1241–1247.
47. Lehmann, M., A. Fournier, I. Selles-Navarro, P. Dergham, A. Sebok, N.
Leclerc, G. Tigyi, and L. McKerracher. 1999. Inactivation of Rho signaling
pathway promotes CNS axon regeneration. J. Neurosci. 19:7537–7547.
48. L’Honore, A., N. J. Lamb, M. Vandromme, P. Turowski, G. Carnac, and A.
Fernandez. 2003. MyoD distal regulatory region contains an SRF binding
CArG element required for MyoD expression in skeletal myoblasts and
during muscle regeneration. Mol. Biol. Cell 14:2151–2162.
49. Li, Y., B. Jiang, W. Y. Ensign, P. K. Vogt, and J. Han. 2000. Myogenic
differentiation requires signalling through both phosphatidylinositol 3-kinase
and p38 MAP kinase. Cell Signal. 12:751–757.
50. Liu, H. W., A. J. Halayko, D. J. Fernandes, G. S. Harmon, J. A. McCauley,
P. Kocieniewski, J. McConville, Y. Fu, S. M. Forsythe, P. Kogut, S. Bellam,
M. Dowell, J. Churchill, H. Lesso, K. Kassiri, R. W. Mitchell, M. B.
Hershenson, B. Camoretti-Mercado, and J. Solway. 2003. The RhoA/Rho
kinase pathway regulates nuclear localization of serum response factor.
Am. J. Respir. Cell Mol. Biol. 29:39–47.
51. Luo, L., Y. J. Liao, L. Y. Jan, and Y. N. Jan. 1994. Distinct morphogenetic
functions of similar small GTPases: Drosophila Drac1 is involved in axonal
outgrowth and myoblast fusion. Genes Dev. 8:1787–1802.
52. Lutz, S., A. Freichel-Blomquist, Y. Yang, U. Rumenapp, K. H. Jakobs, M.
Schmidt, and T. Wieland. 2005. The guanine nucleotide exchange factor
p63RhoGEF, a specific link between Gq/11-coupled receptor signaling and
RhoA. J. Biol. Chem. 280:11134–11139.
53. Marcusohn, J., S. J. Isakoff, E. Rose, M. Symons, and E. Y. Skolnik. 1995.
The GTP-binding protein Rac does not couple PI 3-kinase to insulin-stim-
ulated glucose transport in adipocytes. Curr. Biol. 5:1296–1302.
54. Maruta, H., T. V. Nheu, H. He, and Y. Hirokawa. 2003. Rho family-associ-
ated kinases PAK1 and rock. Prog. Cell Cycle Res. 5:203–210.
55. McBeath, R., D. M. Pirone, C. M. Nelson, K. Bhadriraju, and C. S. Chen.
2004. Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage
commitment. Dev. Cell. 6:483–495.
56. Meriane, M., S. Charrasse, F. Comunale, and C. Gauthier-Rouviere. 2002.
Transforming growth factor beta activates Rac1 and Cdc42Hs GTPases and
the JNK pathway in skeletal muscle cells. Biol. Cell. 94:535–543.
57. Meriane, M., Roux, P., M. Primig, P. Fort, and C. Gauthier-Rouviere. 2000.
Critical activities of Rac1 and Cdc42Hs in skeletal myogenesis: antagonistic
effects of JNK and p38 pathways. Mol. Biol. Cell 11:2513–2528.
58. Minden, A., A. Lin, F. X. Claret, A. Abo, and M. Karin. 1995. Selective
activation of the JNK signaling cascade and c-Jun transcriptional activity by
the small GTPases Rac and Cdc42Hs. Cell 81:1147–1157.
59. Minguell, J. J., A. Erices, and P. Conget. 2001. Mesenchymal stem cells. Exp.
Biol. Med. 226:507–520.
60. Miralles, F., G. Posern, A. I. Zaromytidou, and R. Treisman. 2003. Actin
dynamics control SRF activity by regulation of its coactivator MAL. Cell
113:329–342.
61. Montaner, S., R. Perona, L. Saniger, and J. C. Lacal. 1999. Activation of
serum response factor by RhoA is mediated by the nuclear factor-kappaB
and C/EBP transcription factors. J. Biol. Chem. 274:8506–8515.
62. O’Brien, S. P., K. Seipel, Q. G. Medley, R. Bronson, R. Segal, and M. Streuli.
2000. Skeletal muscle deformity and neuronal disorder in Trio exchange
factor-deficient mouse embryos. Proc. Natl. Acad. Sci. USA 97:12074–12078.
63. Ohyama, M., N. Suzuki, Y. Yamaguchi, M. Maeno, K. Otsuka, and K. Ito.
2002. Effect of enamel matrix derivative on the differentiation of C2C12
cells. J. Periodontol. 73:543–550.
64. Perry, R. L., and M. A. Rudnick. 2000. Molecular mechanisms regulating
myogenic determination and differentiation. Front. Biosci. 5:D750–767.
65. Pittenger, M. F., A. M. Mackay, S. C. Beck, R. K. Jaiswal, R. Douglas, J. D.
Mosca, M. A. Moorman, D. W. Simonetti, S. Craig, and D. R. Marshak.
1999. Multilineage potential of adult human mesenchymal stem cells. Sci-
ence 284:143–147.
66. Posern, G., F. Miralles, S. Guettler, and R. Treis. 2004. Mutant actins that
stabilise F-actin use distinct mechanisms to activate the SRF coactivator
MAL. EMBO J. 23:3973–3983.
67. Pownall, M. E., M. K. Gustafsson, and C. P. Emerson, Jr. 2002. Myogenic
regulatory factors and the specification of muscle progenitors in vertebrate
embryos. Annu. Rev. Cell Dev. Biol. 18:747–783.
68. Qi, C., Y. Zhu, and J. K. Reddy. Peroxisome proliferator-activated receptors,
coactivators, and downstream targets. Cell Biochem. Biophys. 32:187–204.
69. Redd, M. J., L. Cooper, W. Wood, B. Stramer, and P. Martin. 2004. Wound
healing and inflammation: embryos reveal the way to perfect repair. Philos.
Trans. R. Soc. Lond. B. Biol. Sci. 359:777–784.
70. Rikitake, Y., and J. K. Liao. 2005. ROCKs as therapeutic targets in cardio-
vascular diseases. Expert Rev. Cardiovasc. Ther. 3:441–451.
71. Rossman, K. L., C. J. Der, and J. Sondek. 2005. GEF means go: turning on
RHO GTPases with guanine nucleotide-exchange factors. Nat. Rev. Mol.
Cell. Biol. 6:167–180.
72. Rousse, S., F. Lallemand, D. Montarras, C. Pinset, A. Mazars, C. Prunier,
A. Atfi, and C. Dubois. 2001. Transforming growth factor-beta inhibition of
insulin-like growth factor-binding protein-5 synthesis in skeletal muscle cells
involves a c-Jun N-terminal kinase-dependent pathway. J. Biol. Chem. 276:
46961–46967.
73. Saltiel, A. R. 2003. Muscle or fat? Rho bridges the GAP. Cell 113:144–145.
74. Sartorelli, V., K. A. Webster, and L. Kedes. 1990. Muscle-specific expression
of the cardiac alpha-actin gene requires MyoD1, CArG-box binding factor,
and Sp1. Genes Dev. 4:1811–1822.
75. Schmalbruch, H., and D. M. Lewis. 2000. Dynamics of nuclei of muscle fibers
and connective tissue cells in normal and denervated rat muscles. Muscle
Nerve 23:617–626.
76. Settleman, J. 2003. A nuclear MAL-function links Rho to SRF. Mol. Cell
11:1121–1123.
77. Shepherd, P. R. 2005. Mechanisms regulating phosphoinositide 3-kinase
signalling in insulin-sensitive tissues. Acta Physiol. Scand. 183:3–12.
78. Sordella, R., M. Classon, K. Q. Hu, S. F. Matheson, M. R. Brouns, B. Fine,
L. Zhang, H. Takami, Y. Yamada, and J. Settleman. 2002. Modulation of
CREB activity by the Rho GTPase regulates cell and organism size during
mouse embryonic development. Dev. Cell. 2:553–565.
79. Sordella, R., W. Jiang, G. C. Chen, M. Curto, and J. Settleman. 2003.
Modulation of Rho GTPase signaling regulates a switch between adipogen-
esis and myogenesis. Cell 113:147–158.
80. Sotiropoulos, A., D. Gineitis, J. Copeland, and R. Treisman. 1999. Signal-
regulated activation of serum response factor is mediated by changes in actin
dynamics. Cell 98:159–169.
81. Stramer, B., W. Wood, M. J. Galko, M. J. Redd, A. Jacinto, S. M. Parkhurst,
and P. Martin. 2005. Live imaging of wound inflammation in Drosophila
11100 BRYAN ET AL. MOL. CELL. BIOL.
 o
n
 Septem
ber 12, 2018 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
embryos reveals key roles for small GTPases during in vivo cell migration.
J. Cell Biol. 168:567–573.
82. Takano, H., I. Komuro, T. Oka, I. Shiojima, Y. Hiroi, T. Mizuno, and Y.
Yazaki. 1998. The Rho family G proteins play a critical role in muscle
differentiation. Mol. Cell. Biol. 18:1580–1589.
83. Tibbles, L. A., Y. L. Ing, F. Kiefer, J. Chan, N. Iscove, J. R. Woodgett, and
N. J. Lassam. 1996. MLK-3 activates the SAPK/JNK and p38/RK pathways
via SEK1 and MKK3/6. EMBO J. 15:7026–7035.
84. Tidball, J. G. 2005. Inflammatory processes in muscle injury and repair.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 288:R345–353.
85. Travaglione, S., G. Messina, A. Fabbri, L. Falzano, A. M. Giammarioli, M.
Grossi, S. Rufini, and C. Fiorentini. 2005. Cytotoxic necrotizing factor 1
hinders skeletal muscle differentiation in vitro by perturbing the activation/
deactivation balance of Rho GTPases. Cell Death Differ. 12:78–86.
86. Treisman, R., A. S. Alberts, and E. Sahai. 1998. Regulation of SRF
activity by Rho family GTPases. Cold Spring Harb. Symp. Quant. Biol.
63:643–651.
86a.Usui, I., T. Imamura, J. Huang, H. Satoh, and J. M. Olefsky. 2003. Cdc42 is
a Rho GTPase family member that can mediate insulin signaling to glucose
transport in 3T3-L1 adipocytes. J. Biol. Chem. 278:13765–13774.
87. Watson, R. T., M. Furukawa, S. H. Chiang, D. Boeglin, M. Kanzaki, A. R.
Saltiel, and J. E. Pessin. 2003. The exocytotic trafficking of TC10 occurs
through both classical and nonclassical secretory transport pathways in
3T3L1 adipocytes. Mol. Cell. Biol. 23:961–974.
88. Watson, R. T., A. H. Khan, M. Furukawa, J. C. Hou, L. Li, M. Kanzaki, S.
Okada, K. V. Kandror, and J. E. Pessin. 2004. Entry of newly synthesized
GLUT4 into the insulin-responsive storage compartment is GGA depen-
dent. EMBO J. 23:2059–2070.
89. Watson, R. T., and J. E. Pessin. 2001. Intracellular organization of insulin
signaling and GLUT4 translocation. Recent Prog. Horm. Res. 56:175–193.
90. Watson, R. T., and J. E. Pessin. 2001. Subcellular compartmentalization and
trafficking of the insulin-responsive glucose transporter, GLUT4. Exp. Cell
Res. 271:75–83.
91. Watson, R. T., S. Shigematsu, S. H. Chiang, S. Mora, M. Kanzaki, I. G.
Macara, A. R. Saltiel, and J. E. Pessin. 2001. Lipid raft microdomain com-
partmentalization of TC10 is required for insulin signaling and GLUT4
translocation. J. Cell Biol. 154:829–840.
92. Yan, Z., S. Choi, X. Liu, M. Zhang, J. J. Schageman, S. Y. Lee, R. Hart, L.
Lin, F. A. Thurmond, and R. S. Williams. 2003. Highly coordinated gene
regulation in mouse skeletal muscle regeneration. J. Biol. Chem. 278:8826–
8836.
93. Yun, K., and B. Wold. 1996. Skeletal muscle determination and differentia-
tion: story of a core regulatory network and its context. Curr. Opin. Cell Biol.
8:877–889.
94. Zhong, S., S. Sun, and B. B. Teng. 2004. The recombinant adeno-associated
virus vector (rAAV2)-mediated apolipoprotein B mRNA-specific hammer-
head ribozyme: a self-complementary AAV2 vector improves the gene ex-
pression. Genet. Vaccines Ther. 2:5.
95. Zolotukhin, S., B. J. Byrne, E. Mason, I. Zolotukhin, M. Potter, K. Chesnut,
C. Summerford, R. J. Samulski, and N. Muzyczka. 1999. Recombinant
adeno-associated virus purification using novel methods improves infectious
titer and yield. Gene Ther. 6:973–985.
VOL. 25, 2005 REGULATION OF MYOGENESIS AND ADIPOGENESIS BY GEFT 11101
 o
n
 Septem
ber 12, 2018 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
